Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts

FDA 'strongly encouraged' Sandoz to conduct three-way clinical PK/PD study comparing its Zarxio biosimilar to the EU- and U.S.-approved versions of Amgen’s Neupogen; however, the firm succeeded in using only analytical data to justify relevance of studies using the European reference product.

Sandoz Inc.’s success at building an analytical bridge to foreign comparator data for its biosimilar Zarxio (filgrastim-sndz) may prove to be the exception rather than the rule for biosimilar development programs conducted with non-U.S. reference products.

The March 6 approval of Zarxio, a biosimilar to Amgen Inc.’s granulocyte colony-stimulating factor Neupogen (filgrastim), showed it is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America